

Contact: Athena Guo Location: Minneapolis, MN, USA Email: <u>athena@memsurface.com</u> Tel: 612.789.0104 (ext 3) Website: <u>http://www.proteinslides.com</u>

Suisi department of health and human services National Institutes of Health

Larta

National Institutes of Health Commercialization Assistance Program (NIH-CAP)

Company Profile

Industry Sector: Biochips, biosensors, and bioanalytical instrumentation.

Company Overview: MicroSurfaces, Inc. develops and markets cutting edge surface technologies to meet the needs of biosensor and high-through assay users in drug discovery and biomedical research. Technological superiority, combined with a keen understanding of customer needs, has allowed MicroSurfaces to become a leader and enabler of emerging high throughput techniques in proteomics, glycomics and nanomedicine.

Target Market(s): Academics, research institutes and pharmaceutical companies worldwide.

Management

Leadership:

Dr. Athena Guo, President/CEO Prof. Xiaoyang Zhu, Chief technology Officer Dough Johnson, Business advisor/partner Kenneth Cutler, Legal advisor

Scientific Advisory Board:

Carson R. Wagner, Professor of medicinal chemistry, University of Minnesota Qinwei Zhou, Senior Director, Bioanalytical science department, ImClone Systems Inc

Key Value Drivers

Technology: a) "Zero" background surfaces optimized for biosensors, microarrays, and other biophysical/biochemical experiments involving immobilized proteins, glycan, and small molecules; b) Air-stable and fluidic supported lipid bilayers for high throughput screening and analysis of cell-surface interaction.

Competitive Advantage: The "Zero" background surface provides the lowest background and the highest protein activity in the immobilized state. Our supported lipid bilayers technology is the only technology that provides both air-stability and fluidity needed for high fidelity cell surface interaction. To drug developers in pharmaceutical companies and research labs, our technology can cut the time of traditional cell-based assays from weeks & months to hours and make high throughput assays in proteomics highly quantitative and reproducible.

Plan & Strategy: Seeking strategic partner and investment.

*Technology funded by the NCRR and being commericialized under the NIH-CAP.

Product Pipeline

Zero" background functional surfaces:

Functional surfaces for the immobilization of soluble proteins, peptides, antibodies, and other biomolecules used in biosensors, microarrays, and biomedical research.

Cell membrane-mimicking microarrays:

Air stable and fluidic cell membrance mimicking microarrays for the high throughput screening and analysis in proteomics, glycomics, and nanomedicine.